Analyst Price Targets — HSIC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 25, 2026 2:28 pm | — | Barrington | $97.00 | $81.60 | TheFly | Henry Schein price target raised to $97 from $79 at Barrington |
| February 24, 2026 7:47 pm | — | Leerink Partners | $87.00 | $83.35 | TheFly | Henry Schein price target raised to $87 from $75 at Leerink |
| February 23, 2026 9:46 am | — | Robert W. Baird | $100.00 | $79.57 | TheFly | Henry Schein upgraded to Outperform from Neutral at Baird |
| January 20, 2026 11:24 am | Steven Valiquette | Mizuho Securities | $81.00 | $79.98 | TheFly | Henry Schein price target raised to $81 from $74 at Mizuho |
| December 8, 2025 9:15 pm | — | Barclays | $86.00 | $72.86 | TheFly | Henry Schein initiated with an Overweight at Barclays |
| November 5, 2025 2:19 pm | — | Evercore ISI | $90.00 | $71.69 | TheFly | Henry Schein price target raised to $90 from $83 at Evercore ISI |
| November 5, 2025 12:35 pm | — | Barrington | $79.00 | $71.32 | TheFly | Henry Schein price target raised to $79 from $78 at Barrington |
| August 26, 2025 9:37 am | — | Evercore ISI | $83.00 | $69.04 | TheFly | Henry Schein upgraded to Outperform from In Line at Evercore ISI |
| July 14, 2025 12:56 pm | Michael Cherny | Leerink Partners | $75.00 | $70.81 | TheFly | Henry Schein price target raised to $75 from $69 at Leerink |
| May 6, 2025 11:32 am | Michael Petusky | Barrington | $86.00 | $66.24 | TheFly | Henry Schein price target lowered to $86 from $90 at Barrington |
Latest News for HSIC
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Henry Schein, Inc. (NASDAQ: HSIC - Get Free Report) CEO Stanley Bergman sold 10,785 shares of the firm's stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $81.20, for a total transaction of $875,742.00. Following the transaction, the chief executive officer directly owned 309,092 shares in the company,
West Pharmaceutical Services (NYSE: WST - Get Free Report) and Henry Schein (NASDAQ: HSIC - Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, dividends, valuation and profitability. Valuation and Earnings This table compares West
Artisan Partners Limited Partnership raised its position in Henry Schein, Inc. (NASDAQ: HSIC) by 5.7% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,833,041 shares of the company's stock after purchasing an additional 370,837 shares during the quarter. Artisan Partners Limited
Henry Schein, Inc. (HSIC) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.